Amarin AMRN
Amarin FY 2022: revenue $369.2M, down 37%; diluted EPS −$0.26
- Form
- 10-K/A
- Filed
- Period
- Importance
- Routine
- Accession
- 0001193125-23-128994
- Document
- 10-K/A
Key figures from this report
These are the numbers Amarin reported for the year ended Dec 31, 2022, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$369.2M−37% from $583.2M in FY 202110-K income statement, on EDGAR
- Net income−$105.8M−1469% from $7.7M in FY 202110-K income statement, on EDGAR
- Diluted EPS−$0.26−1400% from $0.02 in FY 202110-K income statement, on EDGAR
- Cash and cash equivalents$217.7M−1% from $219.5M in FY 2021Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations−$180.1MAgainst −$66.5M in FY 202110-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Rigel Pharmaceuticals RIGL public float $332M, Jun 30, 2025
- Northwest Biotherapeutics NWBO public float $340M, Jun 30, 2025
- Usana Health Sciences USNA public float $328M, Jun 27, 2025
- Emergent BioSolutions EBS public float $343M, Jun 30, 2025
- Altimmune ALT public float $327M, Jun 30, 2025
